Advertisement

Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial

  • Feikang Xu
  • Weixing Fan
  • Weiping Wang
  • Wei Tang
  • Fuyin Yang
  • Yi Zhang
  • Jun Cai
  • Lisheng Song
  • Chen Zhang
Original Investigation
  • 53 Downloads

Abstract

Rationale

Individuals with schizophrenia are at increased risk of developing metabolic syndrome (MetS) due to their lifestyle and antipsychotic treatment. Our previous study showed that patients with both schizophrenia and MetS present an increased expression and production of tumor necrosis factor-alpha (TNF-alpha). Omega-3 fatty acids have a documented role in suppressing TNF-alpha; therefore, we hypothesized that they may be of value in relieving inflammation and improving metabolic disturbance in patients with both schizophrenia and MetS.

Objectives

This study employed a randomized placebo-controlled trial to investigate the effects of omega-3 fatty acids on MetS in patients with schizophrenia.

Methods

We recruited 80 patients with both schizophrenia and MetS who received long-term olanzapine monotherapy. The patients were randomly assigned to the OMG-3 group (n = 40) or the placebo group (n = 40).

Results

Patients with both schizophrenia and MetS had significantly higher levels of TNF-alpha than the control subjects (Z = − 4.37, P < 0.01). There was a significant correlation between omega-3 fatty acid treatment and reduced triglyceride (TG) levels (Fgroup × time = 13.42; df = 1, 66; P < 0.01) when the patients completed this study. Along with metabolic improvement, omega-3 fatty acids decreased TNF-alpha levels after 12 weeks of treatment (Fgroup × time = 6.71; df = 1, 66; P = 0.012). We also found that the extent of TNF-alpha decrease was significantly correlated with that of TG decrease (r = 0.38, P = 0.001).

Conclusions

Our findings provide suggestive evidence that omega-3 fatty acids have beneficial effects on TG metabolism in patients with both schizophrenia and MetS that parallel decreased inflammation levels.

Keywords

Olanzapine Omega-3 fatty acid TNF-alpha Metabolic syndrome RCT 

Notes

Acknowledgements

We are deeply grateful to all participants.

Funding information

This work was supported by the National Natural Science Foundation of China (81471358 and 81771450), the Shanghai Science and Technology Commission Foundation (14411969000), the Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support (20152530), the Shanghai Municipal Commission of Health and Family Planning Foundation (201540029), and the Shanghai Municipal Commission of Health and Family Planning, Key Developing Disciplines (2015ZB0405).

Compliance with ethical standards

All procedures for this study were reviewed and approved by the Institutional Review Boards of the Shanghai Mental Health Center and other participating institutions. This study was performed in strict accordance with the Declaration of Helsinki and other relevant national and international regulations.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

213_2018_5136_MOESM1_ESM.doc (418 kb)
ESM 1 (DOC 418 kb)

References

  1. Albracht-Schulte K, Kalupahana NS, Ramalingam L, Wang S, Rahman SM, Robert-McComb J, Moustaid-Moussa N (2018) Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. J Nutr Biochem 58:1–16CrossRefPubMedGoogle Scholar
  2. Annamalai A, Kosir U, Tek C (2017) Prevalence of obesity and diabetes in patients with schizophrenia. World J Diabetes 8:390–396CrossRefPubMedPubMedCentralGoogle Scholar
  3. Bao YQ, Lu JX, Wang C, Yang M, Li HT, Zhang XY, Zhu JH, Lu HJ, Jia WP, Xiang KS (2008) Optimal waist circumference cutoffs for abdominal obesity in Chinese. Atherosclerosis 201:378–384CrossRefPubMedGoogle Scholar
  4. Behdani F, Roudbaraki SN, Saberi-Karimian M, Tayefi M, Hebrani P, Akhavanrezayat A, Amlashi SV, Ferns GA, Ghayour-Mobarhan M (2018) Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate. Psychiatry Res 261:243–247CrossRefPubMedGoogle Scholar
  5. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D (2012) Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 37:1901–1911CrossRefPubMedGoogle Scholar
  6. Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA (2008) Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 28:132–137CrossRefPubMedGoogle Scholar
  7. Buckley PF (2001) Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 50:912–924CrossRefPubMedGoogle Scholar
  8. Calder PC (2017) Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans 45:1105–1115CrossRefPubMedGoogle Scholar
  9. Chesney E, Goodwin GM, Fazel S (2014) Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 13:153–160CrossRefPubMedPubMedCentralGoogle Scholar
  10. Cicero AF, Derosa G, Di Gregori V, Bove M, Gaddi AV, Borghi C (2010) Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. Clin Exp Hypertens 32:137–144CrossRefPubMedGoogle Scholar
  11. de Witte L, Tomasik J, Schwarz E, Guest PC, Rahmoune H, Kahn RS, Bahn S (2014) Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr Res 154:23–29Google Scholar
  12. Devaraj S, Valleggi S, Siegel D, Jialal I (2010) Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep 12:110–118CrossRefPubMedPubMedCentralGoogle Scholar
  13. Elagizi A, Lavie CJ, Marshall K, DiNicolantonio JJ, O’Keefe JH, Milani RV (2018) Omega-3 polyunsaturated fatty acids and cardiovascular health: a comprehensive review. Prog Cardiovasc Dis 61:76–85CrossRefPubMedGoogle Scholar
  14. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, Cannon JG, Rogers TS, Klempner MS, Weber PC et al (1989) The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 320:265–271CrossRefPubMedGoogle Scholar
  15. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454CrossRefPubMedGoogle Scholar
  16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome—an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112:2735–2752CrossRefPubMedGoogle Scholar
  17. Gurusamy J, Gandhi S, Damodharan D, Ganesan V, Palaniappan M (2018) Exercise, diet and educational interventions for metabolic syndrome in persons with schizophrenia: A systematic review. Asian J Psychiatr 36:73–85CrossRefPubMedGoogle Scholar
  18. Huang M, Yu L, Pan F, Lu S, Hu S, Hu J, Chen J, Jin P, Qi H, Xu Y (2018) A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first episode schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 81:122–130CrossRefPubMedGoogle Scholar
  19. Kao AC, Spitzer S, Anthony DC, Lennox B, Burnet PWJ (2018) Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota. Transl Psychiatry 8:66CrossRefPubMedPubMedCentralGoogle Scholar
  20. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276CrossRefPubMedGoogle Scholar
  21. Kim YS, Xun P, He K (2015) Fish consumption, long-chain omega-3 polyunsaturated fatty acid intake and risk of metabolic syndrome: a meta-analysis. Nutrients 7:2085–2100CrossRefPubMedPubMedCentralGoogle Scholar
  22. Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J (2004) Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol 61:232–238CrossRefGoogle Scholar
  23. Labrousse VF, Leyrolle Q, Amadieu C, Aubert A, Sere A, Coutureau E, Gregoire S, Bretillon L, Pallet V, Gressens P, Joffre C, Nadjar A, Laye S (2018) Dietary omega-3 deficiency exacerbates inflammation and reveals spatial memory deficits in mice exposed to lipopolysaccharide during gestation. Brain Behav Immun 73:427–440CrossRefPubMedGoogle Scholar
  24. Li Z, Qi D, Chen J, Zhang C, Yi Z, Yuan C, Wang Z, Hong W, Yu S, Cui D, Fang Y (2013) Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-alpha) in the Chinese patients with major depressive disorder: a prospective longitudinal study. Psychoneuroendocrinology 38:107–114CrossRefPubMedGoogle Scholar
  25. Lorente-Cebrián S, Costa AG, Navas-Carretero S, Zabala M, Martínez JA, Moreno-Aliaga MJ (2013) Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. J Physiol Biochem 69:633–651CrossRefPubMedGoogle Scholar
  26. Memon RA, Grunfeld C, Moser AH, Feingold KR (1993) Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 132:2246–2253CrossRefPubMedGoogle Scholar
  27. Meyer JM (2002) A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63:425–433CrossRefPubMedGoogle Scholar
  28. Mozurkewich EL, Berman DR, Vahratian A, Clinton CM, Romero VC, Chilimigras JL, Vazquez D, Qualls C, Djuric Z (2018) Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines. BMC Pregnancy Childbirth 18:261CrossRefPubMedPubMedCentralGoogle Scholar
  29. O’Mahoney LL, Matu J, Price OJ, Birch KM, Ajjan RA, Farrar D, Tapp R, West DJ, Deighton K, Campbell MD (2018) Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials. Cardiovasc Diabetol 17:98CrossRefPubMedPubMedCentralGoogle Scholar
  30. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan WQ, Li PP, Lu WJ, Watkins SM, Olefsky JM (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142:687–698CrossRefPubMedPubMedCentralGoogle Scholar
  31. Penninx BWJH, Lange SMM (2018) Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci 20:63–73Google Scholar
  32. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF (2007) The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 48:751–762CrossRefPubMedGoogle Scholar
  33. Pramyothin P, Khaodhiar L (2010) Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 17:460–466CrossRefPubMedGoogle Scholar
  34. Rahmani E, Jamilian M, Dadpour B, Nezami Z, Vahedpoor Z, Mahmoodi S, Aghadavod E, Taghizadeh M, Beiki Hassan A, Asemi Z (2018) The effects of fish oil on gene expression in patients with polycystic ovary syndrome. Eur J Clin Investig 48:e12893CrossRefGoogle Scholar
  35. Shearer GC, Borkowski K, Puumala SL, Harris WS, Pedersen TL, Newman JW (2018) Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids. Prostaglandins Leukot Essent Fat Acids 128:1–10CrossRefGoogle Scholar
  36. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E 3rd, Kufe DW (1988) Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 6:344–350CrossRefPubMedGoogle Scholar
  37. Stapel B, Sieve I, Falk CS, Bleich S, Hilfiker-Kleiner D, Kahl KG (2018) Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells. J Psychiatr Res 105:95–102CrossRefPubMedGoogle Scholar
  38. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29:15–31CrossRefPubMedGoogle Scholar
  39. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU (2015) Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 14:339–347CrossRefPubMedPubMedCentralGoogle Scholar
  40. von Schacky C (2006) A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc Health Risk Manag 2:251–262CrossRefGoogle Scholar
  41. Wang P, Cai J, Ni J, Zhang J, Tang W, Zhang C (2016) The NCAN gene: schizophrenia susceptibility and cognitive dysfunction. Neuropsychiatr Dis Treat 12:2875–2883Google Scholar
  42. Zhang Y, Chen M, Wu Z, Chen J, Yu S, Fang Y, Zhang C (2013) Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results. PLoS One 8:e72652CrossRefPubMedPubMedCentralGoogle Scholar
  43. Zhang Y, Chen M, Chen J, Wu Z, Yu S, Fang Y, Zhang C (2014) Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype. Psychopharmacology 231:2211–2218CrossRefPubMedGoogle Scholar
  44. Zhang C, Chen MJ, Wu GJ, Wang ZW, Rao SZ, Zhang Y, Yi ZH, Yang WM, Gao KM, Song LS (2016) Effectiveness of antipsychotic drugs for 24-month maintenance treatment in first-episode schizophrenia: evidence from a community-based “real-world” study. J Clin Psychiatry 77:e1460–e1466CrossRefPubMedGoogle Scholar
  45. Zhang C, Fang X, Yao P, Mao Y, Cai J, Zhang Y, Chen M, Fan W, Tang W, Song L (2017a) Metabolic adverse effects of olanzapine on cognitive dysfunction: a possible relationship between BDNF and TNF-alpha. Psychoneuroendocrinology 81:138–143CrossRefPubMedGoogle Scholar
  46. Zhang C, Zhang Y, Cai J, Chen M, Song L (2017b) Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis. Pharmacogenomics J 17:92–97CrossRefPubMedGoogle Scholar
  47. Zhang C, Lv Q, Fan W, Tang W, Yi Z (2017c) Influence of CFH gene on symptom severity of schizophrenia. Neuropsychiatr Dis Treat 13:697–706Google Scholar
  48. Zhang Y, Fang XY, Fan WX, Tang W, Cai J, Song LS, Zhang C (2018) Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study. Psychopharmacology 235:1191–1198CrossRefPubMedGoogle Scholar
  49. Zhou H, Guo ZR, Yu LG, Hu XS, Xu BH, Liu HB, Wu M, Zhou ZY (2010) Evidence on the applicability of the ATPIII, IDF and CDS metabolic syndrome diagnostic criteria to identify CVD and T2DM in the Chinese population from a 6.3-year cohort study in mid-eastern China. Diabetes Res Clin Pract 90:319–325CrossRefPubMedGoogle Scholar
  50. Zhu Y, Wang Z, Ni J, Zhang Y, Chen M, Cai J, Li X, Zhang W, Zhang C (2014) Genetic variant in NDUFS1 gene is associated with schizophrenia and negative symptoms in Han Chinese. J Hum Genet 60:11–16CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Schizophrenia Program, Shanghai Mental Health CenterShanghai Jiao Tong University School of MedicineShanghaiChina
  2. 2.Department of PsychiatryJinhua Second HospitalJinhuaChina
  3. 3.Department of Psychiatry, Wenzhou Kangning HospitalWenzhou Medical UniversityWenzhouChina
  4. 4.Shanghai Key Laboratory of Brain Functional Genomics (Ministry of Education), School of Psychology and Cognitive ScienceEast China Normal UniversityShanghaiChina

Personalised recommendations